Using AI to Create New Parkinson’s Treatments: Q&A with Mattias Alder
Alder, CEO of Gain Therapeutics, discusses how the Magellan platform was used in the creation of GT-02287.
October 24, 2026
Alder, CEO of Gain Therapeutics, discusses how the Magellan platform was used in the creation of GT-02287.
In an interview with Pharm Exec Associate Editor Don Tracy, Lene Oddershede, SVP, Natural & Technical Sciences, Novo Nordisk Foundation
Data from the Phase III ALINA trial show that Alecensa reduced the risk of disease recurrence or death by 76%
Approval was based on positive data from Takeda’s Phase III VISIBLE 2 study, which displayed long-term clinical remission in approximately
Acquisition includes rights to marketing in the European Economic Area, Thailand, South Korea, and other regions for oral treatment of
While human infections of the virus are rare, a strain recently appeared in dairy cows before infecting a human in
Rahman discusses the new opportunities that digital twins present to researchers.
According to results of the study, 46% of patients with giant cell arteritis administered Rinvoq achieved sustained remission from weeks
The latest news for pharma industry insiders.
Click the title above for a link to open the Pharmaceutical Executive April 2024 issue in an interactive PDF format.
The latest news for pharma industry insiders.
Amid lingering questions and uncertainty, a look at ways pharma companies can prioritize incorporating the Inflation Reduction Act into their
The latest news for pharma industry insiders.
Damien Bailly, president of established markets at Astellas, discusses why partnerships and collaborations are a critical organizational—and wider ecosystem—imperative in
Greater Than One’s Chief Strategy Officer, Andrew Bast, shares his takeaways from 2024 Rare Disease Summit in Philadelphia, PA.
In this Pharmaceutical Executive video interview, Currax Pharmaceuticals, CEO, George Hampton, discusses factors that are contributing to ongoing supply issues
role of machine learning in an AI video editor AI video editors can drastically cut down the time it takes
Pharma companies and RPM manufacturers must work together to find solutions to make DCT more commonly available.
Why this role provides a critical ‘boot camp’ for future pharma leaders.
Partnership also includes an agreement for Arvinas to sell its preclinical AR-V7 program to Novartis.
Treatment was initially approved in 2017 for the same indication in children aged 12 and up.
New methods allow the antiseizure treatment to be crushed and mixed with water for oral suspension or for use through
Decree comes amid the FDA’s 2021 inspection of Philips’ Murrysville facility and the subsequent voluntary recall of its sleep and
Joint venture aims to implement Invenra’s B-Body bispecific antibody platform to enhance Astellas’ research and development efforts.
A combination of data from the EMERGENT-4 trial and pooled data from the EMERGENT program showed the promise of KarXT
Collaboration aims to advance the development of treatments for multiple neurodegenerative conditions, including amyotrophic lateral sclerosis.
According to the letter, the FDA believes that the investigational apomorphine infusion device is not ready for approval in its
Dovato is the first oral, two-drug, single-tablet regimen approved for patients 12 years of age and older who are living
The latest news for pharma industry insiders.
FDA’s program will provide guidance to the development of the company’s Delphi-MD technology.
Abecma was found to triple progression-free survival compared to standard regimens with a 51% decline in the risk of disease
In this Pharmaceutical Executive video interview, Currax Pharmaceuticals, CEO, George Hampton, discusses their drug Contrave and the data they have
Decision to discontinue marketing authorizations for Relyvrio/Albrioza comes as a result of topline results from the Phase III PHOENIX trial
The deal, which is worth approximately $13.1 billion, is part of J&J MedTech’s goal to expand into high-growth markets.
Agreement comes as Teva aims to strengthen its biosimilar portfolio as part of its “Pivot to Growth” strategy.
Early results have demonstrated that mRNA-3927 has led to a 70% reduction in the relative risk for metabolic decompensation events
Approval comes amid positive results from TRILUMINATE trial, which demonstrated improvement in 90% of participants treated for a leaky tricuspid
Fanapt was previously approved by the FDA in 2009 as an antipsychotic treatment for schizophrenia.
Approval would mark first HER2-targeted therapy for biliary tract cancer in the United States.
The concussion test, which shows results after 15 minutes, can help evaluate patients up to 24 hours after injury, company
Treatment approved in combination with ravulizumab or eculizumab, representing minority demographic still suffering after receiving C5 inhibitor therapy for extravascular
The network will work with DiRx and MakoRX.
The latest news for pharma industry insiders.
In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with
Deal aims to commercialize XTX301 for treating advanced solid tumors by leveraging Xilio’s tumor-activated immuno-oncology therapies.
Phase II clinical study showed that children as young as six years of age with hepatitis B virus could benefit
The study used technology developed by a variety of companies, including RYLTI.
The news comes less than a year after Pfizer announced that IPG would handle this role.
Approval of Vafsen (vadadustat) based on promising results from the INNO2VATE program and additional safety data from use in Japan
Both products are designed to help radiologists.
Winrevair is the first FDA-approved activin signaling inhibitor therapy for pulmonary arterial hypertension.
Action marks the first FDA-approved blood screening test for malaria.
Alexander discusses the broader implications the case could have on FDA’s ability to regulate the industry.
Reportedly, the oral weight loss pill VK2735 showed promising signs of effectiveness and a tolerable safety profile.
In this Pharmaceutical Executive video interview, Marie Teil, Global Head of UCB’s Women of Childbearing Age Program, talks about the
Action marks the first FDA approval of a long-acting treatment for adult patients with neuromyelitis optica spectrum disorder who are
The agency released guidelines for vaccinations guidelines for children as young as 6 months old.
The latest news for pharma industry insiders.
Duvyzat (givinostat) is histone deacetylase inhibitor that was previously granted priority review, orphan drug designation, and rare pediatric disease designation
In this Pharmaceutical Executive video interview, Optum Rx clinical pharmacist, Arash Sadeghi, discusses the three drugs featured in their Drug
Despite not having a positive outcome, safety profiles for Keytruda and Lynparza were consistent with previous findings.
The drug was recently cleared to treat cardiovascular risks, making it eligible for Medicare Part D.
In this Pharmaceutical Executive video interview, Kaveh Vahdat, Founder and President of RiseOpp, talks about what’s coming marketing with the
Cold Spring Harbor Laboratory details how the new tool will help reduce common barriers to trial participation.
Tryvio (aprocitentan) approved in combination with other antihypertensive drugs to lower hypertension in adults whose blood pressure is not adequately
The acquisition will bolster AstraZeneca’s ability to develop radioconjugates for cancer treatments.
Label expansion approval for Iclusig (ponatinib) addresses adult patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.
In this Pharmaceutical Executive video interview, Kaveh Vahdat, Founder and President of RiseOpp, discusses the impact AI will have on
In a unanimous decision, the committee recommended Carvykti based on promising data from the Phase III CARTITUDE-4 study, which showed
As part of the partnership, BeiGene will serve as a sponsor at LLS events.
The latest news for pharma industry insiders.
Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) was granted accelerated approval for the treatment of adult patients with noncirrhotic nonalcoholic steatohepatitis (NASH).
CAR T-cell therapy Breyanzi (lisocabtagene maraleucel) approved for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma
Tevimbra (tislelizumab-jsgr) has been approved as a monotherapy for adult patients with unresectable or metastatic esophageal squamous cell carcinoma who
In this Pharmaceutical Executive video interview, Murray Aitken, Executive Director of the IQVIA Institute for Human Data Science, discusses why
In this Pharmaceutical Executive video interview, Kaveh Vahdat, Founder and President of RiseOpp, discusses how AI could have helped address
Acquisition is highlighted by eneboparatide, Amolyt’s Phase III peptide for hypoparathyroidism with a novel mechanism of action.
The new season could bring with it more possibilities for renewal in the biotech sector, as our coverage this month
The voluntary recall was ordered due to potential silicon particulate exposure.
In this Pharmaceutical Executive interview, Jill Jaroch, Senior Director, Women’s Health & Urology Marketing at Astellas, discusses the decision to
Four steps to maximize the impact of medical information services as an engagement gateway.
In this Pharmaceutical Executive video interview, Murray Aitken, Executive Director of the IQVIA Institute for Human Data Science, discusses findings
Regeneron’s PCSK9 inhibitor approved to reduce low-density lipoprotein cholesterol in patients 8 years of age and older with heterozygous familial
Starting June 1, Boehringer Ingelheim plans to cap inhaler products for respiratory diseases at $35 per month for eligible patients.
BeiGene’s Brukinsa is a small molecule Bruton’s tyrosine kinase inhibitor indicated as a monotherapy and in combination with other treatments
Because of the unique trial design of the Phase III TRAILBLAZER-ALZ 2 study, the FDA is seeking additional input regarding
Relyvrio did not significantly alter amyotrophic lateral sclerosis disease progression as measured by the ALSFRS-R total score at Week 48
FDA approves Wegovy (semaglutide) to lower the risk of major adverse cardiovascular events in adults with known heart disease and
In this Pharmaceutical Executive video interview, Daniel Ayala, Chief Security and Trust Officer, Dotmatics discusses how the data integrity landscape
Opdivo (nivolumab) plus cisplatin and gemcitabine was found to improve overall survival and progression-free survival compared with chemotherapy alone in
Eli Lilly continues to emphasize the potential harm that could come with using GLP-1 receptor agonists for off-label purposes.
The company plans to spend the coming years strengthening its market position and pipeline while also clearing its issues with
Agreement to focus on research, option, and licensing for discovery of dual tumor-associated antigen-targeting antibodies.
The biosimilars Wyost and Jubbonti (denosumab-bddz) were approved as interchangeable products for Prolia and Xgeva for the treatment of osteoporosis,
The partnership has the goal of improving patient education and treatment directions.
Rebranding aims to align company with its parent company and other subsidiaries.
In this Pharmaceutical Executive video interview, Daniel Ayala, Chief Security and Trust Officer, Dotmatics, discusses data security threats from human
The agency teamed up with the software company to develop platforms and networks to collect de-identified data.
The agency updated its recommendations after a vote by the ACIP advisory committee.
Simon discusses a recent survey ICON conducted with professionals in obesity-related clinical research.
Phase III DAYBREAK study found consistent safety with Zeposia in patients with relapsing forms of multiple sclerosis.
JAMA commentary suggests that issues such as high costs, access, and equity will stop patients from obtaining GLP-1 agonists to
New guidance suggests that CMS may be ramping up Sunshine Act auditing activities, potentially resulting in monetary liability for noncompliant
Cardinal Health report highlights new biosimilar treatments, legislative developments, and multiple industry perspectives.
Commentary cites lower control over health plan costs and the potential bias for prescribing drugs through influence from drug manufacturers.
OSE-230 was developed to activate a unique mechanism for resolving chronic inflammation, focusing on modulation of macrophages and neutrophils.
NVL-520 is a novel, brain-penetrant, ROS1-selective tyrosine kinase inhibitor under evaluation for patients with metastatic ROS1-positive non–small cell lung cancer.
The FDA granted Allecra with a five-year marketing exclusivity extension for Exblifep (cefepime/enmetazobactam) through the Generating Antibiotic Incentives Now Act.
Results of the study determined that adult flu vaccination rates among Medicaid populations were significantly low, highlighting other health inequities.
FDA has approved the medication in adults and children with allergies.
The site will have a staff of 400 employees.
Murray Aitken, Executive Director of the IQVIA Institute for Human Data Science, discusses key findings from their Global Use of
The gallery will be a part of the HLTH Europe event and will be open to all attendees.
The FDA has assigned a supplemental Biologics License Application submitted by Regeneron and Sanofi for Dupixent in the treatment of
The agency issued a statement reminding the public that it has not approved any such devices for this use.
Results of a study conducted by the National Institutes of Health indicate that the Paxlovid prevented a substantial number of
Funds expected to advance multiple programs into clinical studies, including FMC-376, which targets KRASG12C cancers.
Early-stage trial results indicate that NLRP3 inflammasome inhibitors were able to achieve nearly the same weight loss as Wegovy while
Letter emphasizes the need to protect children from potentially harmful medical advice spread on social media.
The FDA assigned the biologics license application for linvoseltamab to treat relapsed/refractory multiple myeloma with a Prescription Drug User Fee
Anderson discusses the complexities of planning for a global launch and the common mistakes companies make that cause problems along
Amtagvi is the first one-time, individualized T-cell therapy approved by the FDA for any solid tumor cancer.
The FDA has assigned a Prescription Drug User Fee Act action date of August 20, 2024, for Servier’s New Drug
The FDA has also approved Tagrisso (osimertinib) as a monotherapy for the first-line treatment of patients with locally advanced or
Multivitamine și minerale Vitaminele și mineralele joacă sute de roluri esențiale în organism, de la întărirea oaselor până la întărirea
Amid shifting healthcare cost strategies, how manufacturers can apply past lessons to best support patients and help boost drug adherence.
Investigators harness machine learning to evaluate response to sertraline treatment for major depressive disorder.
How a multipronged approach to staff recruitment can accelerate trial success.
In an interview with Pharm Exec Associate Editor Don Tracy, Raj Verma, Chief Diversity, Culture, and Experience Officer, Sanofi, discusses
Iris Kuss, head of clinical development, and Jorge Ortiz, head of medical affairs, discuss the company’s recent presentation at ASCO
Novartis’ and Roche’s Xolair (omalizumab) is indicated to treat severe allergic reactions after accidental exposure to one or more foods
The FDA previously granted accelerated approval to Tepmetko for metastatic non–small cell lung cancer harboring MET exon 14 skipping alterations.
This acquisition will add asthma treatment A1O-001 to GSK’s portfolio.
Click the title above for a link to open the Pharmaceutical Executive February 2024 issue in an interactive PDF format.
Treatment aims to reduce the risk of finger or toe amputation due to frostbite.
Pancreatic adenocarcinoma is the most common form of pancreatic cancer, with more than 60,000 diagnoses per year in the United
Roche halts agreement with Repare Therapeutics to develop and commercialize camonsertib just weeks after triggering a $40 million milestone payment
Embracing business imperatives such as operational efficiency and a focus on a patient-centric approach can help pharma leaders provide a
In this video interview with Pharm Exec Associate Editor Miranda Schmalfuhs, Dr. Jo Varshney, CEO & Founder of VeriSIMLife, discusses
Takeda expects Eohilia single-dose stick packs will be available by the end of February for patients aged 11 years and
Key steps in relationship-building beyond just treatment options.
Novel oral orexin receptor 2 agonist produced statistically significant and clinically meaningful improvements in wakefulness compared with placebo in patients
Joint venture aims to submit an Investigational New Drug application to the FDA by early next year for treatment that
The use of artificial intelligence (AI) in drug development has been hampered by issues that have caused a gap between
According to the study conducted by Technavio, North America will contribute to 37% of the expected growth.
BioNTech will invest $200 million and get access to Autolus’ manufacturing sites.
2024 Life Sciences Accounting & Reporting Congress
The three-year initiative comes with $15 million in funding.
Data from the ENHANCE-3 trial of magrolimab in combination with azacitidine plus Venclexta showed futility and an increased risk of
The agreement will strengthen Novartis’ oncology pipeline.
In a Phase I trial, data suggest that Amgen’s maridebart cafraglutide (MariTide) may allow patients to take lower and less
The FDA assigned a Prescription Drug User Fee Act action date of June 7, 2024, to an application that would
Synchron’s brain-computer interface device is being developed to allow patients with mobility challenges to operate certain technology with their mind.
The drugmaker will directly acquire three finish-fill sites as part of the deal.
Novartis rescinds rights to to develop and commercialize multi-tyrosine kinase inhibitor dovitinib due to a material breach by Allarity for
The company has struggled to supply the drug to patients due to overwhelming popularity.
The agency issued the warning against three brands of unapproved eyedrops designed to look like an approved brand.
Beyfortus (nirsevimab-alip), a monoclonal antibody that protects against respiratory syncytial virus-associated lower respiratory tract disease, experienced higher than anticipated demand
In an interview with Pharm Exec Associate Editor Don Tracy, Shubh Goel, Head of Immuno-Oncology and Gastrointestinal Tumors, US Oncology
The US Department of Health and Human Services has initiated a comprehensive strategy to address the escalating syphilis rates, as
DELFI-Tumor Fraction assay was developed to improve noninvasive assessment of tumor burden and monitoring of treatment efficacy and resistance in
App aims to leverage digital technology to significantly reduce pharmacy costs.
Aduhelm (aducanumab-avwa) was granted accelerated approval by the FDA in June 2021 despite misgivings from the agency’s Peripheral and Central
Eli Lilly advertisement emphasizes that advancements in in medicine can lead to improved population health.
CAR T-cell therapy Breyanzi (lisocabtagene maraleucel) to be evaluated in patients with relapsed or refractory follicular lymphoma and mantle cell
This is Takeda’s second approval in chronic inflammatory demyelinating polyneuropathy this month after the FDA approved HyQvia to protect against
The agency recognized the medication as a significant advancement for the treatment of IPF.
Enhertu has been approved by the FDA for indications in breast cancer, non-small cell lung cancer, and gastroesophageal junction adenocarcinoma.
Report comes after the FDA seized thousands of counterfeit Ozempic units.
Substance use disorder is a complex condition that demands innovative solutions, one of which that has shown promise is the
In an interview with PharmExec Associate Editor Don Tracy, Jingsong Wang discusses Nona Biosciences’ recent exclusive license agreement with Pfizer
Study finds that individuals who took GLP-1 agonists for a long duration had a lower risk of going on to
Atypical antidepressant linked to severe adverse effects and death as a result of misuse.
FDA leadership notes that the overall rate of secondary T-cell cancers among patients administered CAR T-cell therapies appears to be
The FDA previously approved Dupixent in May 2022 to treat eosinophilic esophagitis in patients aged 12 years and older.
New FDA guidelines require manufacturers to add boxed warnings to CAR T-cell therapy products.
Embracing new digital-based tools is critical throughout the healthcare landscape to prepare for the rise of telemedicine as a permanent
NK010 is reportedly the first Chinese trial of its kind to be approved by the FDA.
The EVOKE-01 trial compared Trodelvy with docetaxel for the treatment of patients with metastatic or advanced non-small cell lung cancer
McCloskey discusses the steps that drug developers can take to ensure better CLD outcomes in 2024.
Opdivo plus Yervoy shows promise in treating patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer.
Will the FDA ultimately step in and mandate a credible effort to eradicate the mindset that long-term adherence is not
In an interview with Nicholas Saraceno, Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses the changing role of
Lutathera plus long-acting release octreotide lowered the risk of disease progression or death by 72% in patients with somatostatin receptor-positive
Analytics capabilities are no longer a nice-to-have, but a necessity to build and maintain a successful business and competitive edge.
According to the university, new nanotech scaffolding can be used to support tissue growth.
Today’s FDA approval amends a previously granted accelerated approval for Balversa (erdafitinib) to treat patients with metastatic urothelial carcinoma whose
Webinar Date/Time: Thu, Feb 15, 2024 11:00 AM EST
Sun Pharmaceutical Industries will purchase Taro’s outstanding shares for $43 each, which will total $348 million.
Researchers believe low numbers in the use of direct-to-consumer healthcare services could rapidly trend up.
HyQvia is the only subcutaneous immune globulin infusion that can be administered once per month.
New analysis for 2023 shows signs of post-pandemic recovery; breast cancer remains most studied disease area.
Company displayed findings at the 2024 Winter Clinical Dermatology Conference in Hawaii demonstrating significant improvements in atopic dermatitis and seborrheic
Roots Analysis report suggests increase can be attributed to the growing demand for advanced therapies and biologics.
The device can produce AI-assisted readings.
The BioThrax vaccine is indicated for active immunization to prevent anthrax disease caused by Bacillus anthracis in individuals aged 18
Measuring the relationship between a product’s reimbursement position and performance begins with gathering key data points for as many products
The survey is part of the brand’s new marketing campaign.
RC88 is under evaluation for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.